Objective: To characterize and further compare the immune cell populations of the tumor microenvironment (TME) in both clear cell and papillary renal cell carcinoma (RCC) using heavy metal-labeled ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the U.S. Food and Drug Administration (FDA) for patients with high-risk Bacillus Calmette-Guérin ...

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...

Aggressive Digital Papillary Adenocarcinoma (DPA ... For instance, a study utilizing in situ hybridization found that all examined DPA tumors tested positive for HPV42, while other sweat gland ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

with carcinoma in situ (CIS), with or without papillary tumours. Bladder cancer is one of the more common forms of cancer. According to the Centers for Disease Control and Prevention, about 57,000 ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

with carcinoma in situ (CIS) with or without papillary tumors, ImmunityBio announced in a news release. 1 The MHRA will now review the application for potential approval in the United Kingdom. “MHRA’s ...

with carcinoma in situ (CIS), with or without papillary tu CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant ...